Author: Bandera Alessandra Marchetti Giulia Gori Andrea
Publisher: Informa Healthcare
ISSN: 1354-3776
Source: Expert Opinion on Therapeutic Patents, Vol.15, Iss.9, 2005-09, pp. : 1115-1131
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
The current antiretroviral therapy has improved the clinical outcome of HIV-infected patients. However, drug toxicity, the emergence of drug-resistant HIV variants and the incomplete reconstitution of immune response underline the need for additional therapeutic approaches. Adjuvant therapies with immunomodulants, such as cytokines, immunosuppressants, or compounds selectively targeting HIV-specific immunity, are being intensively investigated as potential supplements to antiretroviral therapy. Although much data have been generated, there has been little evidence of the clinical efficacy of these strategies to date, and the need for new effective and reproducible immune surrogate markers able to identify the actual improvement derived from an immunotherapeutic strategy is becoming a priority. The demonstration of a possible role in inducing a better control of HIV infection and the identification of settings in which these therapies should be more effective will be essential if immunomodulants are to be included in the therapeutic arma-mentarium against HIV.
Related content
Tackling resistance in HIV infection
Inpharma, Vol. 1, Iss. 1303, 2001-01 ,pp. :
Cryptococcal disease and HIV infection
Expert Opinion on Pharmacotherapy, Vol. 6, Iss. 15, 2005-12 ,pp. :
Treatment of HIV infection with raltegravir
By Chirch Lisa M Morrison Sidonie Steigbigel Roy T
Expert Opinion on Pharmacotherapy, Vol. 10, Iss. 7, 2009-05 ,pp. :
Antifungal use in HIV infection
By Mylonakis Eleftherios Marty Francisco
Expert Opinion on Pharmacotherapy, Vol. 3, Iss. 2, 2002-02 ,pp. :